The translational challenge in the development of new and effective therapies for endometriosis: a review of confidence from published preclinical efficacy studies

被引:31
|
作者
Pullen, Nick [1 ]
Birch, Claire L. [1 ]
Douglas, Garry J. [1 ]
Hussain, Qasim [1 ]
Pruimboom-Brees, Ingrid [1 ]
Walley, Rosalind J. [1 ]
机构
[1] Pfizer Global Res & Dev, Sandwich CT13 9NJ, Kent, England
关键词
endometriosis; preclinical model end-points; translation; CHRONIC PELVIC PAIN; SMALL NERVE-FIBERS; EUTOPIC ENDOMETRIUM; LAPAROSCOPIC SURGERY; ECTOPIC ENDOMETRIUM; CLINICAL-TRIALS; CYST-FORMATION; IN-VITRO; INHIBITOR; MODELS;
D O I
10.1093/humupd/dmr030
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
BACKGROUND: Endometriosis is a benign gynaecological condition that presents symptoms of chronic pelvic pain and the ectopic growth of endometrial lesions at sites on the peritoneum. Few new approaches to the management of the disease symptoms and progression have emerged in decades. The cornerstone of developing new therapies is the confidence and translational value placed in the preclinical models used to assess efficacy of emerging approaches. METHODS: We systematically reviewed preclinical efficacy data from rodent and non-human primates, evaluating the effects of an investigational agent or target reported in PubMed between 2000 and 2010. We evaluated the reports for which model and end-points had been used to determine efficacy, whether there was evidence of independent replication, whether techniques had been incorporated into the experimental design to eliminate potential bias and whether there was a confirmation of drug exposure or target engagement in the study. RESULTS: We identified 94 publications that met our criteria for review. Efficacy studies were conducted in a wider range of different models with no clear consensus on which model or end-point has the most translational value. The large majority of studies either did not report what measures were incorporated into the design to address potential bias or account for it or did not confirm whether the specified target was engaged. CONCLUSIONS: Greater scrutiny of the preclinical efficacy models, end-points and experimental designs is needed if the desire of translating novel treatment approaches is to be realized for women with endometriosis.
引用
收藏
页码:791 / 802
页数:12
相关论文
共 24 条
  • [1] Plants as source of new therapies for endometriosis: a review of preclinical and clinical studies
    Meresman, Gabriela F.
    Goette, Martin
    Laschke, Matthias W.
    HUMAN REPRODUCTION UPDATE, 2021, 27 (02) : 367 - 392
  • [2] The development of neural stimulators: a review of preclinical safety and efficacy studies
    Shepherd, Robert K.
    Villalobos, Joel
    Burns, Owen
    Nayagam, David A. X.
    JOURNAL OF NEURAL ENGINEERING, 2018, 15 (04)
  • [3] Selective Pharmacologic Therapies for Dry Eye Disease Treatment: Efficacy, Tolerability, and Safety Data Review from Preclinical Studies and Pivotal Trials
    Bridgitte Shen Lee
    Melissa Toyos
    Paul Karpecki
    Jessica Schiffbauer
    John Sheppard
    Ophthalmology and Therapy, 2022, 11 : 1333 - 1369
  • [4] Selective Pharmacologic Therapies for Dry Eye Disease Treatment: Efficacy, Tolerability, and Safety Data Review from Preclinical Studies and Pivotal Trials
    Shen Lee, Bridgitte
    Toyos, Melissa
    Karpecki, Paul
    Schiffbauer, Jessica
    Sheppard, John
    OPHTHALMOLOGY AND THERAPY, 2022, 11 (04) : 1333 - 1369
  • [5] Lipid-based nanodelivery approaches for dopamine-replacement therapies in Parkinson's disease: From preclinical to translational studies
    Karthivashan, Govindarajan
    Ganesan, Palanivel
    Park, Shin-Young
    Lee, Ho-Won
    Choi, Dong-Kug
    BIOMATERIALS, 2020, 232
  • [6] SYSTEMATIC REVIEW OF COST EFFECTIVENESS OF ULTRA-ORPHAN THERAPIES: LESSON LEARNED FROM PUBLISHED HTAS AND STUDIES
    Aggarwal, S.
    Topaloglu, H.
    Kumar, S.
    VALUE IN HEALTH, 2015, 18 (03) : A8 - A8
  • [7] Targeted therapies for KRAS-mutant non-small cell lung cancer: from preclinical studies to clinical development-a narrative review
    Santarpia, Mariacarmela
    Ciappina, Giuliana
    Spagnolo, Calogera Claudia
    Squeri, Andrea
    Passalacqua, Maria Ilenia
    Aguilar, Andres
    Gonzalez-Cao, Maria
    Giovannetti, Elisa
    Silvestris, Nicola
    Rosell, Rafael
    TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (02) : 346 - 368
  • [8] Management of adrenoleukodystrophy: From pre-clinical studies to the development of new therapies
    Ma, Chui Yan
    Li, Cheng
    Zhou, Xiaoya
    Zhang, Zhao
    Jiang, Hua
    Liu, Hongsheng
    Chen, Huanhuan Joyce
    Tse, Hung-Fat
    Liao, Can
    Lian, Qizhou
    BIOMEDICINE & PHARMACOTHERAPY, 2021, 143
  • [9] Experimental Models of Glaucoma: A Powerful Translational Tool for the Future Development of New Therapies for Glaucoma in Humans-A Review of the Literature
    Evangelho, Karine
    Mastronardi, Claudio A.
    de-la-Torre, Alejandra
    MEDICINA-LITHUANIA, 2019, 55 (06):
  • [10] Development of Rebif® New Formulation for MS treatment:: consolidated results from preclinical and phase I studies
    Driebergen, R.
    Jaber, A.
    Aotonelli, M.
    Giovannoni, G.
    Schellekens, H.
    Simsarian, J.
    MULTIPLE SCLEROSIS, 2007, 13 : S53 - S53